PRESS RELEASE published on 07/13/2023 at 13:00, 1 year 2 months ago Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
PRESS RELEASE published on 07/05/2023 at 13:00, 1 year 2 months ago Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
PRESS RELEASE published on 07/03/2023 at 07:00, 1 year 2 months ago Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/22/2023 at 22:05, 1 year 3 months ago Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/05/2023 at 14:00, 1 year 3 months ago Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
PRESS RELEASE published on 06/01/2023 at 22:05, 1 year 3 months ago Moderna to Present at Upcoming Conferences in June 2023
PRESS RELEASE published on 05/30/2023 at 14:00, 1 year 3 months ago Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
PRESS RELEASE published on 05/19/2023 at 13:00, 1 year 4 months ago Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
PRESS RELEASE published on 05/04/2023 at 12:30, 1 year 4 months ago Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 05/03/2023 at 22:05, 1 year 4 months ago Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
Published on 09/28/2024 at 02:06, 1 day 3 hours ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 3 hours ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 5 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 15 hours 27 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 6 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 7 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 10 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 10 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 11 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 11 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024